INT48722

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 7.66
Pain Relevance 1.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SERPINE1) extracellular region (SERPINE1) plasma membrane (SERPINE1)
Anatomy Link Frequency
plasma 4
cartilage 2
SERPINE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 17 99.96 Very High Very High Very High
cytokine 32 99.90 Very High Very High Very High
dexamethasone 1 96.84 Very High Very High Very High
Inflammation 78 96.48 Very High Very High Very High
cINOD 12 95.56 Very High Very High Very High
cva 10 95.28 Very High Very High Very High
Inflammatory mediators 1 94.88 High High
bradykinin 20 94.60 High High
Arthritis 3 90.92 High High
agonist 2 88.48 High High
Disease Link Frequency Relevance Heat
Pressure Volume 2 Under Development 1 100.00 Very High Very High Very High
Disorder Of Lipid Metabolism 7 99.58 Very High Very High Very High
Thrombophilia 40 99.52 Very High Very High Very High
Hypertension 61 99.48 Very High Very High Very High
Thrombosis 12 97.40 Very High Very High Very High
Metabolic Syndrome 23 97.00 Very High Very High Very High
INFLAMMATION 85 96.48 Very High Very High Very High
Atherosclerosis 72 96.08 Very High Very High Very High
Metastasis 25 96.08 Very High Very High Very High
Insulin Resistance 40 95.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Univariate and multivariate analysis of uPA and PAI-1 mRNA values for MFS
Negative_regulation (analysis) of Gene_expression (values) of PAI-1 mRNA
1) Confidence 0.43 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1564186 Disease Relevance 0.68 Pain Relevance 0
PGE2 (and PGE1) inhibited PAI-1 mRNA expression and secretion in a dose-dependent manner with an IC50 (for antigen secretion) of 4.6 x 10(-10) M and 8.7 x 10(-10) M, respectively.
Negative_regulation (inhibited) of Gene_expression (expression) of PAI-1 mRNA
2) Confidence 0.42 Published 1994 Journal Mol. Cell. Endocrinol. Section Abstract Doc Link 7525383 Disease Relevance 0.28 Pain Relevance 0.22
As shown in Figure 4, the expression levels of PAI-1 and COX-2 measured in the independent STs without CB were found to be very similar to the levels detected in CBs and significantly different from those detected in STs after CB.
Negative_regulation (levels) of Gene_expression (expression) of PAI-1
3) Confidence 0.41 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779463 Disease Relevance 0.45 Pain Relevance 0.06
Table 1 lists differences in RNA expression values of PAI-1, COX-2 and ERBB2 for paired samples of each patient.
Negative_regulation (values) of Gene_expression (expression) of PAI-1
4) Confidence 0.41 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779463 Disease Relevance 0.24 Pain Relevance 0.13
The inhibition of PAI-1 levels by cytokines and reagents which stimulate cartilage resorption (i.e., TNF alpha, interleukin-1 alpha, retinoic acid) and enhancement by cytokines which counter it (i.e., TGF-beta, bFGF) further implicate plasminogen activator in the mechanism(s) of cartilage degradation in diseases such as arthritis.
Negative_regulation (inhibition) of Gene_expression (levels) of PAI-1 in cartilage associated with disease, arthritis and cytokine
5) Confidence 0.40 Published 1994 Journal Biochim. Biophys. Acta Section Abstract Doc Link 8054359 Disease Relevance 0.56 Pain Relevance 0.43
PAI-1 represent the most important physiological inhibitor of tissue-type plasminogen activator (TPA) in plasma and elevated levels have been implicated in the pathogenesis of thromboembolic disease (Ridker 1992).
Negative_regulation (inhibitor) of Gene_expression (represent) of PAI-1 in plasma associated with cva
6) Confidence 0.24 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663435 Disease Relevance 0.48 Pain Relevance 0.13
Hypertension is often associated with impaired fibrinolysis, usually expressed by increased levels of plasminogen activator inhibitor type 1 (PAI-1) and decreased activity of tissue plasminogen activator (t-PA).31 Combination therapy with amlodipine and atorvastatin improved the fibrinolytic balance more than either single agent in hypertensive hypercholesterolemic patients with insulin resistance.31
Negative_regulation (impaired) of Gene_expression (expressed) of PAI-1 associated with hypertension and insulin resistance
7) Confidence 0.11 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2686256 Disease Relevance 1.03 Pain Relevance 0.04
Treatment is generally associated with increased HDL cholesterol levels; decreased blood pressure, plasma triglyceride levels, small dense LDL cholesterol particles, PAI-1 levels and albumin excretion rates; in addition to decreased glucose levels and reduced hemoglobin A1C levels (Day 1999; Kruszynska et al 2000; Lebovitz et al 2001; Freed et al 2002).
Negative_regulation (decreased) of Gene_expression (levels) of PAI-1 in plasma associated with pressure volume 2 under development and disorder of lipid metabolism
8) Confidence 0.10 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350146 Disease Relevance 0.77 Pain Relevance 0.05
As a consequence coagulation inhibitors are consumed, and fibrinolysis is inhibited by the production of plasminogen activator inhibitor 1 [1].
Negative_regulation (inhibited) of Gene_expression (production) of activator inhibitor 1
9) Confidence 0.07 Published 2006 Journal Crit Care Section Body Doc Link PMC1794466 Disease Relevance 0.71 Pain Relevance 0.09
This stimulated production of plasminogen activator inhibitor-1 could decrease MMP activation.
Negative_regulation (decrease) of Gene_expression (production) of plasminogen activator inhibitor-1 associated with metalloproteinase
10) Confidence 0.06 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779427 Disease Relevance 0.22 Pain Relevance 0.29
Increased survivin levels are significantly associated with high nuclear grade, negative hormone receptor status, HER2 over-expression, VEGF expression, and high urokinase-type plasminogen activator and plasminogen activator inhibitor-1 levels.
Negative_regulation (inhibitor) of Gene_expression (expression) of plasminogen activator
11) Confidence 0.03 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 1.06 Pain Relevance 0
This cytokine may reduce tissue production of the plasminogen activator and increase production of the inhibitor of this activator, an event that may result in thrombus formation [86], [87].
Negative_regulation (reduce) of Gene_expression (production) of plasminogen activator associated with thrombosis and cytokine
12) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2930857 Disease Relevance 0.59 Pain Relevance 0.20
This cytokine may reduce tissue production of the plasminogen activator and increase production of the inhibitor of this activator, an event that may result in thrombus formation [86], [87].
Negative_regulation (reduce) of Gene_expression (production) of plasminogen activator associated with thrombosis and cytokine
13) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2930857 Disease Relevance 0.59 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox